The Enterprise Value as of December 2025 (TTM) for Terns Pharmaceuticals, Inc. (TERN) is 2.30B

According to Terns Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.30B. This represents a change of 786.79% compared to the average of 259.25M of the last 4 quarters.

Terns Pharmaceuticals, Inc. (TERN) Historical Enterprise Value (quarterly & annually)

How has TERN Enterprise Value performed in the past?

The mean historical Enterprise Value of Terns Pharmaceuticals, Inc. over the last ten years is 318.12M. The current 2.30B Enterprise Value has changed 72.17% with respect to the historical average. Over the past ten years (40 quarters), TERN's Enterprise Value was at its highest in in the March 2023 quarter at 642.86M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Terns Pharmaceuticals, Inc. (TERN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Terns Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Terns Pharmaceuticals, Inc. (TERN) Average Enterprise Value

How has TERN Enterprise Value performed in the past?

The current Enterprise Value of Terns Pharmaceuticals, Inc. (TERN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Terns Pharmaceuticals, Inc. (TERN) Enterprise Value vs. Peers

How is TERN’s Enterprise Value compared to its peers?

Terns Pharmaceuticals, Inc.’s Enterprise Value is greater than Tourmaline Bio, Inc. (1.20B), greater than ORIC Pharmaceuticals, Inc. (1.06B), greater than Precigen, Inc. (1.22B), greater than Immatics N.V. (919.66M), greater than Enliven Therapeutics, Inc. (1.15B), greater than Amylyx Pharmaceuticals, Inc. (985.24M), greater than Nektar Therapeutics (1.22B), greater than Relay Therapeutics, Inc. (1.33B), greater than Syndax Pharmaceuticals, Inc. (1.94B), greater than Inhibrx Biosciences, Inc. (1.13B),

Build a custom stock screener for Terns Pharmaceuticals, Inc. (TERN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Terns Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Terns Pharmaceuticals, Inc. (TERN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Terns Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.